JEFFERSON, N.C., Dec. 19 /PRNewswire/ -- Next Safety, Inc., a leader in developing pulmonary drug delivery devices, today announced verification of a significant breakthrough in pulmonary science that provides high efficacy delivery of drugs to the lungs.
Advanced optical characterization techniques performed by a third party laboratory showed that 99.8% of the droplets delivered by Next Safety's pulmonary drug delivery devices were between one and three microns in diameter, and the droplets separated sufficiently in space and time to be absorbed into the alveoli of the lungs.
The company has already demonstrated more rapid delivery of nicotine to
the bloodstream through the lungs than possible with cigarettes.
Next Safety's advance means that:
-- Drugs previously restricted to intravenous or oral delivery such as
antibiotics, analgesics, anti-emetics, peptides and proteins like
insulin and vaccines can be delivered to the human body directly
through the lungs.
-- The pharmaceutical industry can offer medications with systemic
delivery without needles, syringes and intravenous lines.
Four of the ten largest global pharmaceutical companies have expressed interest in the company's pulmonary business. Next Safety expects to begin a bidding process for its pulmonary business in early 2008.
Next Safety's immediate and ongoing research studies focus on the pulmonary delivery of nicotine, albuterol, tobramyacin and long chain peptide and protein molecules. Nicotine delivery and other clinical findings from brain imaging and arterial blood studies conducted in partnership with a major U.S. medical institution will be announced in the first quarter of 2008.
"Previous nicotine replacement products have helpe
|SOURCE Next Safety, Inc.|
Copyright©2007 PR Newswire.
All rights reserved